Korea Investment CORP Makes New Investment in Danaher Corporation $DHR

Korea Investment CORP purchased a new position in shares of Danaher Corporation (NYSE:DHR) in the 2nd quarter, Holdings Channel reports. The firm purchased 415,041 shares of the conglomerate’s stock, valued at approximately $79,057,000.

Other large investors also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Danaher by 303.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock worth $56,777,000 after purchasing an additional 186,584 shares during the last quarter. Puzo Michael J acquired a new stake in Danaher during the 2nd quarter worth approximately $8,624,000. Legal & General Group Plc boosted its position in Danaher by 1.0% during the 4th quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate’s stock worth $1,029,061,000 after buying an additional 43,169 shares during the period. Handelsbanken Fonder AB grew its holdings in Danaher by 10.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 289,223 shares of the conglomerate’s stock worth $55,091,000 after acquiring an additional 28,425 shares during the last quarter. Finally, Advisors Capital Management LLC increased its position in Danaher by 14.0% in the 4th quarter. Advisors Capital Management LLC now owns 54,845 shares of the conglomerate’s stock valued at $12,555,000 after acquiring an additional 6,720 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DHR has been the subject of several analyst reports. Argus dropped their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Piper Sandler initiated coverage on Danaher in a report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price objective for the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 target price on shares of Danaher in a research report on Wednesday, July 22nd. HSBC reduced their price target on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Finally, Weiss Ratings raised Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $228.91.

Danaher Stock Performance

Shares of Danaher stock opened at $219.42 on Friday. The business has a 50-day moving average price of $195.80 and a two-hundred day moving average price of $192.61. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a market cap of $154.25 billion, a P/E ratio of 38.97, a PEG ratio of 2.69 and a beta of 0.78.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the prior year, the company earned $0.77 EPS. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.